



# BIORESORBABLE URETHRAL BULKING AGENT



o.r. consulting®  
[www.orconsulting.biz](http://www.orconsulting.biz)


Tél. +41.22.592.64.74  
4B, chemin de Joran - 1260 Nyon  
[info@orconsulting.biz](mailto:info@orconsulting.biz)

UROOLON™ KIT

# UROLON™ KIT

## IDEALLY SUITED FOR WOMEN WITH MILD TO MODERATE SUI

### UROLON™ BRIDGING THE TREATMENT GAP BETWEEN CONSERVATIVE AND SURGICAL TREATMENT



#### Urolon™ Benefits

- High Biocompatibility
- Excellent safety profile
- Bioresorbable, low-risk procedure
- Sustained efficacy up to 18-month follow-up
- Cost-effective (low injection volume)
- High patient satisfaction

#### Urolon™

• Is an injectable implant, indicated for transurethral submucosal implantation:

- 30% polycaprolactone (PCL) microspheres
- 70% carboxymethylcellulose (CMC) gel carrier

• Triggers a controlled foreign body response leading to **neocollagenesis**

#### PCL & CMC

- Have been used for decades in CE and FDA approved medical devices
- Are both highly biocompatible and bioresorbable
- CMC carrier-gel provides immediate (bulking) effect
- PCL microspheres trigger a controlled foreign body response leading to neocollagenesis
  - Replacing lost collagen in SUI patients
- Bi-phasic resorption of PCL microspheres
  - First phase: average molecular weight decreases while PCL volume and mass remain the same
  - Second phase: mass loss and total bioresorption of PCL microspheres

#### REFERENCES

1. Ford AA, et al. Mid-urethral sling operations for stress urinary incontinence in women. *Cochrane Database Syst Rev.* 2015;7:CD006375.
2. Tamanini JT, et al. Macroplastique implantation system for female stress urinary incontinence: long-term follow-up.
3. Pai A & Al-Singary W. Durability, safety of polyacrylamide hydrogel (Bulkamid®) in the management of stress and mixed urinary incontinence: three year follow up outcomes. *Cent European J Urol.* 2015;68(4):428-433.
4. Futyma K, et al. Nonabsorbable urethral bulkingness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up. *Eur J Obstet Gynecol Reprod Biol.* 2016;207:68-72.
5. Zajda J & Farag F. Urolastic-a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up. *Adv Urol.* 2013;2013:724082.
6. Siddiqui ZA, Abboudi H, Crawford R, Shah S. Intraurethral bulking agents for the management of female stress urinary incontinence: a systematic review. *Int Urogynecol J.* 2017 Sep;28(9):1275-1284.



#### CROSS-SECTION THROUGH URETHRA

Muscle Layer

Central Filler Substance showing collagen fibers

Urethral Lumen

Continent Urethra

Incontinent Urethra

#### MODE OF ACTION Urolon™



Urolon™ injection, giving immediate bulking effect.



PCL microspheres provide sustained bulking effect



Total bioresorption of PCL Microspheres

ORDER INFORMATION  
UROLON KIT

Réf 1001924



o.n. consulting®  
www.orconsulting.biz

Tél. +41.22.592.64.74  
4B, chemin de Joran - 1260 Nyon  
info@orconsulting.biz